Anti-IL-4R therapy led improvement in SNOT-22 (p = 0.0002), corticosteroid bursts (p ≤ 0.0001), median number of antibiotic courses for respiratory disease (p = 0.0468) when compared with anti-IL-5/IL-5R and anti-IgE biologic therapies. Here, IL5 is linked to respiratory system disorder.